Biotechnology company CytoDyn Inc. (OTCQB: CYDY) yesterday announced that its management team will be hosting an investment community conference call to provide an update on the company’s latest clinical trial and regulatory developments. The call is scheduled for Tuesday, April 18, 2017, at 4:00 p.m. ET. Interested participants and investors can access the conference call by dialing 877-407-2986 from the United States and Canada or 201-378-4916 from international locations. Additionally, a live audio webcast of the call will be made available under the Investor Relations section of www.CytoDyn.com. This webcast will be archived for 60 days for the convenience of those unable to attend the live call. A replay will also be made available through June 18, 2017, by dialing 877-660-6853 from the U.S. and Canada or 201-612-7415 from international locations, using conference ID 13652328.
To view the full press release, visit http://nnw.fm/9jKYc
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed phase 2 clinical trials with demonstrated antiviral activity in man and is currently in phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven phase 1 and phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV and to pursue non-HIV indications where CCR5 and its ligand CCL5 may be involved. For more information on the company, please visit www.cytodyn.com.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer